share_log

UBS Adjusts Sino Biopharmaceutical's Price Target to HK$7.5 From HK$8, Keeps at Buy

UBS Adjusts Sino Biopharmaceutical's Price Target to HK$7.5 From HK$8, Keeps at Buy

瑞銀將信和生物製藥的目標股價從8港元調整至7.5港元,維持買入
MT Newswires ·  2022/08/25 05:35

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論